Literature DB >> 32329378

Validation and clinical application of dried blood spot assay for quantitative assessment of edoxaban in healthy adults.

Ling He1, Roohi Gajee1, Raj Mangaraj2, Michael P Waldron3, Karen S Brown1.   

Abstract

Aim: Dried blood spot (DBS) is a sampling approach that offers several advantages over plasma and whole blood (WB) sampling, but several factors, such as hematocrit and temperature, can adversely affect quantitation. Methodology & results: In an open-label, three-way crossover study in healthy subjects, we explored the correlation between DBS, WB and plasma samples, and between DBS samples from finger-prick and venipuncture blood for measuring edoxaban and its metabolite M-4 using LC-MS/MS. The methods were validated comprehensively. The incurred sample reanalysis experiments demonstrated quantitation reproducibility in all three matrices. Overall, there was a good correlation (near perfect concordance for edoxaban) among plasma, WB and DBS measurements. M-4 concentrations in DBS and WB were lower than in plasma.
Conclusion: These results indicate using DBS may be used as an alternative methodology to measure edoxaban pharmacokinetics.

Entities:  

Keywords:  bioanalytical method validation; concordance; dried blood spot; edoxaban; finger prick; incurred sample analysis

Year:  2020        PMID: 32329378     DOI: 10.4155/bio-2019-0180

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  1 in total

1.  Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min.

Authors:  Ophelia Yin; Tarundeep Kakkar; Anil Duggal; Masakatsu Kotsuma; Minggao Shi; Hans Lanz; Michael A Grosso
Journal:  Clin Pharmacol Drug Dev       Date:  2021-12-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.